JIL 1 1 2013

INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

RE	CEL	1/0-	
		VET	T

Atty. Docket NonDEN 787.0041-01		Appln. No.	09/893,615	
Applicant	Gerald W. FISCHER et al.			JOL 1 7 2003
Filing Date	June 29, 2001	Group:	1645	TECH CENTED
				1600/2900

		U.S. PATENT	DOCUMENTS			3/23()
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date

		FOREIGN PATI	ENT DOCUMENT	S		
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
V26	WO 93/17044	9-2-93	PCT			English Document
V	WO 96/09321	3-28-96	PCT			English Document

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
1/26	Borrebaeck, Antibody Engineering, 2nd Ed., Oxford University Press, NY (1995).
V	Carruthers and Kabat, Mediation of Staphylococcal Adherence to Mucosal Cells by Lipoteichoic Acid, <i>Infect Immun.</i> 40 :444-46 (1983).
	Current Methods in Hybridoma Formation, Bartal et al. (ed.) <i>Methods of Hybridoma Formation</i> , Humana Press, Clifton, New Jersey (1987).
	De Kimpe et al., The Cell Wall Components Peptidoglycan and Lipoteichoic Acid From <i>S. aureus</i> Act in Synergy to Cause Shock and Multiple Organ Failure, <i>Proc. Nat. Acad. Sci. (USA)</i> 92 :10359-63 (1995).
	Fischer et al., Improved Preparation of Lipoteichoic Acids, Eur. J. Biochem. 133:523-30 (1983).
/	Fournier, Staphylococcus aureus, Vaccines and Immunotherapy, Ch. 13, pp. 166-77 (1991).
\	Gonzalez and Hill, The Current Status of Intravenous Gamma-globulin Use in Neonates, <i>J. Ped. Infect. Dis.</i> 8: 315-22 (1989).

	$ \alpha$ α			
Examiner	XXX	Date Considered	9	03
*Examiner:		ed, whether or not citation is in conform formance and not considered. Include it.		
Form PTO 14	149	Patent and Trademark Office	- U.S	S. Department of Commerce



INFORMATION DISCLOSURE CITATION



Atty. Decker No.	7787.0041-01	Appln. No.	09/893,615	JUL 1 7 2003
Applicant	Gerald W. FISCHER et al.			IECH CENTER 1600/2000
Filing Date	June 29, 2001	Group:	1645	1000/2900

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
· \B6	Green et al., Antigen-Specific Human Monoclonal Antibodies from Mice Engineered with Human Ig Heavy and Light Chain YACs, <i>Nat. Genet.</i> 7: 13-21 (1994).
	Hancock, Bacterial Cell Surface Carbohydrates: Structure and Assembly, <i>Biochem. Soc. Trans.</i> 25 :183-87 (1997).
	Jendeberg et al., Engineering of Fc ₁ and Fc ₃ From Human Immunoglobulin G to Analyse Subclass Specificity for Staphylococcal Protein A, <i>J. Immunol. Methods</i> 201 :25-34 (1997).
	Lee, The Prospects for Developing a Vaccine Against Staphylococcus aureus, Trends In Micro. 4 :162-66 (1996).
	LoBuglio et al., Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response, <i>P.N.A.S.</i> 86 :4220-24 (1989).
	Low et al., Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain, <i>J Mol Biol</i> 260 :359-68 (1996).
	McDermid et al., A Porcine Model of <i>Staphylococcus epidermidis</i> Catheter-Associated Infection, J. <i>Infect. Dis.</i> 168 : 897-903 (1993).
	Nealon and Mattingly, Role of Cellular Lipoteichoic Acids in Mediating Adherence of Serotype III Strains of Group B Streptococci to Human Embryonic, Fetal, and Adult Epithelial Cells, <i>Infect Immun.</i> 43 :523-30 (1984).
	Oshima et al., Comparison of Cell Wall Teichoic Acid Fractions Isolated from Three Different Encapsulated Strains of Staphylococcus epidermidis, Ann. Microbiol. 135:353-65 (1984).
	Peterson et al., Effect of Protein A on Staphylococcal Opsonization, <i>Infection and Immunity</i> 15 :760-64 (1977).
	Peterson et al., Influence of Encapsulation on Staphylococcal Opsonization and Phagocytosis by Human Polymorphonuclear Leukocytes, <i>Infection and Immunity</i> 19 :943-49 (1978).
	Quie et al., Defective Phagocytosis of Staphylococci, Ann. N. Y. Acad. Sci. 236:233-43 (1974).
	Romero-Vivas et al., Mortality Associated with Nosocomial Bacteremia due to Methicillin-Resistant Staphylococcus aureus, Clin. Infect. Dis. 21: 1417-23 (1995).
	Salton, The Bacterial Cell Envelope - A Historical Perspective, in JM. Ghuyson and R. Hakenbeck (Ed.), <i>Bacterial Cell Wall</i> , Elsevier Science BV, Amsterdam, pp. 1-22 (1994).
A	Schwab et al., Increased Adherence of <i>Staphylococcus aureus</i> From Cystic Fibrosis Lungs to Airway Epithelial Cells, <i>Am. Rev. Respir. Dis.</i> 148 :365-69 (1993).

Examiner	Sent	Date Considered	5/	03
*Examiner:	Initial if reference considered, whether or a through citation if not in conformance and communication to applicant.			
Form PTO 144	Patent and	d Trademark Office	e - U.S.	Department of Commerce





INFORMATION DISCLOSURE CITATION

CATELOT & TO SEE	IN ORMATIO	N DISCLOSURE	CHAHON	RFCr.
Atty. Docket No.	7787.0041-01	Appln. No.	09/893,615	CEIVED
Applicant	Gerald W. FISCHER et al.			JUL 17 2002
Filing Date	June 29, 2001	Group:	1645	TECH CENTER

		OTHER DOCUMENTS (Including Author Title Date Portinent Pages Etc.)
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	VBP	Shulman et al., A Better Cell Line for Making Hybridomas Secreting Specific Antibodies, <i>Nature</i> 276 :269-70 (1978).
1		Takada et al., Molecular and Structural Requirements of a Lipoteichoic Acid From <i>Enterococcus hirae</i> ATCC 9790 for Cytokine-Inducing, Antitumor, and Antigenic Activities, <i>Infection and Immunity</i> 63 :57-65 (1995).
		Teti et al., Adherence of Group B Streptococci to Adult and Neonatal Epithelial Cells Mediated by Lipoteichoic Acid, <i>Infect Immun.</i> 55 :3057-64 (1987).
		Wagner et al., The Diversity of Antigen-Specific Monoclonal Antibodies from Transgenic Mice Bearing Human Immunoglobulin Gene Miniloci, <i>Eur J Immunol</i> 24 :2672-81 (1994).
		Wagner et al., Antibodies Generated from Human Immunoglobulin Miniloci in Transgenic Mice, Nuc. Acids Res. 22:1389-93 (1994).
		Waldvogel, Staphylococcus aureus (Including Toxic Shock Syndrome), In Mandell, G.L. et al. (ed.) Principles and Practices of Infectious Diseases, Third Edition, Churchill Livingstone, New York, Ch. 173, pp. 1489-1510 (1990).
,		Winter et al., Making Antibodies by Phage Display Technology, <i>Annu. Rev. Immunol.</i> 12 :433-55 (1994).

Examiner

Date Considered

*Examiner:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449

Patent and Trademark Office - U.S. Department of Commerce